Sign Up Today and Learn More About Encoded Therapeutics Stock
Invest in or calculate the value of your shares in Encoded Therapeutics or other pre-IPO companies through EquityZen's platform.
Encoded Therapeutics Stock
Encoded Therapeutics is a Harnessing the regulatory genome to create next-generation molecular therapies.
About Encoded Therapeutics Stock
Founded
2014
Headquarters
South San Francisco, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Encoded Therapeutics Press Mentions
Stay in the know about the latest news on Encoded Therapeutics
Encoded Therapeutics Announces FDA Alignment, Initiation of Pivotal Study, and ASGCT Presidential Symposium Presentation of ETX101 in Dravet Syndrome
biospace • Mar 25, 2026
Encoded Therapeutics Announces FDA Alignment, Initiation...
pharmiweb • Mar 25, 2026
Improve Recruitment Outcomes Through More Diverse Clinical Trials, Upcoming Webinar Hosted by Xtalks
prnewswire • Mar 23, 2026
Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
biospace • Jan 13, 2026
Encoded Therapeutics Announces U.S. FDA Breakthrough Ther...
pharmiweb • Jan 13, 2026
Encoded Therapeutics Management
Leadership team at Encoded Therapeutics
Chairman
Sean P. Nolan
Co-Founder and Chief Scientific Officer
Stephanie Tagliatela
Join now and verify your accreditation status to gain access to:
- Encoded Therapeutics Current Valuation
- Encoded Therapeutics Stock Price
- Encoded Therapeutics Management
- Available deals in Encoded Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Encoded Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Encoded Therapeutics Revenue and Financials
- Encoded Therapeutics Highlights
- Encoded Therapeutics Business Model
- Encoded Therapeutics Risk Factors
- Encoded Therapeutics Research Report from SACRA Research
Trading Encoded Therapeutics Stock
How to invest in Encoded Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Encoded Therapeutics through EquityZen funds. These investments are made available by existing Encoded Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Encoded Therapeutics stock?
Shareholders can sell their Encoded Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."